Market Research Report
EUROPE ATOPIC DERMATITIS DRUGS MARKET FORECAST 2018-2026
|Published by||Inkwood Research||Product code||626307|
|Published||Content info||77 Pages
Delivery time: 1-2 business days
|EUROPE ATOPIC DERMATITIS DRUGS MARKET FORECAST 2018-2026|
|Published: April 16, 2018||Content info: 77 Pages||
Europe Atopic dermatitis drugs market continues to escalate at 3.20% of CAGR over the forecasting years. The deliberated base year for the market study is 2017. The forecasting years are 2018-2026. Increasing focus on systematic therapies and growing awareness among populace are the key factors proliferating the growth of the market in the region.
The developing healthcare infrastructure is one of the major factor augmenting the growth of the market in the region. The various drug class mentioned in the Atopic Dermatitis Drugs market are topical antibiotics, topical antihistamines, topical corticosteroids, topical moisturizers/emollients, topical calcineurin inhibitors, immunomodulators, off-label therapies, systemic agents, PDE-4 inhibitor, and interleukin inhibitor. The region comprises of key countries like UK, France, Russia, Germany and rest of Europe. Among all, UK is the leading country in the region by possessing a colossal share in the market. However, stringent regulations for product approval is one of the major roadblocks of the market to grow in the region.
Astellas Pharma Inc., Leo Pharma, Allergan Plc, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Aqua Pharmaceuticals (An Almirall Company), Encore Dermatology, Galderma SA, Stiefel Laboratories Inc., Meda Pharmaceuticals (Mylan), Sanofi SA, Astellas Pharma Inc., Novartis Ag, Bayer Ag, Pfizer, and Valent Pharmaceutical Inc. are the dominant organization in the market.